You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ertugliflozin

Showing 1 - 25 of 34
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetes, Diabetic Kidney Disease, Hypertension Trial (Salt-Diet and/or Ertugliflozin)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Salt-Diet and/or Ertugliflozin
  • (no location specified)
Feb 3, 2023

Type 2 Diabetes Trial (Ertugliflozin, Placebo, Glycemic Rescue)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Ertugliflozin
  • +2 more
  • (no location specified)
Sep 9, 2022

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety &

Not yet recruiting
  • Efficacy
  • +2 more
  • Combinations of Oral Blood Glucose Lowering Drugs
  • (no location specified)
Oct 3, 2022

Liver Fat, Liver Fibrosis, Glycemic Control Trial (Ertugliflozin 5 mg, 15mg)

Not yet recruiting
  • Liver Fat
  • +5 more
  • Ertugliflozin 5 mg, 15mg
  • (no location specified)
Nov 30, 2022

Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction Trial in Seoul (Ertugliflozin, Placebo)

Recruiting
  • Mitral Valve Insufficiency
  • Left Ventricular Systolic Dysfunction
  • Ertugliflozin
  • Placebo
  • Seoul, Korea, Republic of
  • +2 more
Jun 19, 2022

Heart Failure, Diastolic, Diabetes, Type 2 Trial in Cleveland (Ertugliflozin 5 mg, Placebo oral tablet)

Recruiting
  • Heart Failure, Diastolic
  • Diabetes Mellitus, Type 2
  • Ertugliflozin 5 mg
  • Placebo oral tablet
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center
Dec 10, 2021

Heart Failure With Reduced Ejection Fraction, Congestion Trial in New York (Ertugliflozin, Placebo)

Not yet recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Congestion
  • Ertugliflozin
  • Placebo
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 29, 2021

Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • +3 more
  • Ertugliflozin 5 mg
  • Placebo 5mg
  • Klagenfurt, Kärnten, Austria
  • +8 more
Jan 31, 2022

Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)

Not yet recruiting
  • Sleep Apnea
  • Ertugliflozin 15 mg
  • Placebo
  • New Haven, Connecticut
  • +1 more
Jan 24, 2023

Four Second Line Pharmacological Strategies in Type 2 Diabetes

Active, not recruiting
  • Cardiovascular Events
  • +2 more
  • SGLT2 inhibitor
  • +3 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Feb 17, 2022

Type 2 Diabetes, Diabetic Kidney Disease, Diabetic Nephropathy Trial in Amsterdam (Ertugliflozin 15 mg)

Recruiting
  • Type 2 Diabetes Mellitus
  • +6 more
  • Ertugliflozin 15 mg
  • Amsterdam, Netherlands
    VU University Medical Center
Mar 30, 2021

Left Ventricular Remodeling in Type 2 Diabetic Acute Myocardial

Recruiting
  • Myocardial Infarction
  • Diabetes Mellitus, Type 2
  • SGLT2 inhibitor
  • Seoul, Korea, Republic of
    Seoul St. Mary's Hospital
Mar 5, 2023

Type 2 Diabetes Trial in Worldwide (Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo)

Recruiting
  • Type 2 Diabetes Mellitus
  • Ertugliflozin 5 mg
  • +4 more
  • Birmingham, Alabama
  • +99 more
Nov 25, 2022

Heart Failure With Nonischemic Cardiomyopathy Trial in Seoul (Ertugliflozin, Placebo)

Not yet recruiting
  • Heart Failure With Nonischemic Cardiomyopathy
  • Ertugliflozin
  • Placebo
  • Seoul, Korea, Republic of
    Severance Hospiatal
Aug 5, 2020

Type 2 Diabetes Trial (Ertugliflozin, Placebo to Ertugliflozin)

Completed
  • Type 2 Diabetes Mellitus
  • Ertugliflozin
  • Placebo to Ertugliflozin
  • (no location specified)
May 28, 2020

Hypertension, Diabetes, Type 2 Trial in Los Angeles (drug, device, other)

Withdrawn
  • Hypertension
  • Diabetes Mellitus, Type 2
  • Ertugliflozin
  • +6 more
  • Los Angeles, California
    Cedars-Sinai Medical Center
Jan 10, 2020

Type 2 Diabetes Trial (Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Ertugliflozin 5 mg
  • +6 more
  • (no location specified)
Mar 25, 2019

Ketoses, Metabolic Trial (SGLT2 inhibitor + low-carb diet, + low-carb diet)

Not yet recruiting
  • Ketoses, Metabolic
  • SGLT2 inhibitor + low-carb diet
  • placebo + low-carb diet
  • (no location specified)
Dec 28, 2022

Type 2 Diabetes Trial (Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo matching ertugliflozin)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Ertugliflozin 5 mg
  • +4 more
  • (no location specified)
Nov 13, 2018

Type 2 Diabetes Trial (Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Unlabeled ertugliflozin for oral use
  • +2 more
  • (no location specified)
Aug 20, 2018

Second Line Therapy Medications in Diabetes

Recruiting
  • Diabetes Mellitus, Type 2
  • Wilmington, Delaware
  • +4 more
Dec 22, 2021

Type 2 Diabetes Trial (Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo for ertugliflozin 5 mg)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Ertugliflozin 5 mg
  • +7 more
  • (no location specified)
Aug 15, 2018

Type 2 Diabetes Trial (Matching Placebo to Ertugliflozin 5 mg, Matching Placebo to Ertugliflozin 10 mg, Matching Placebo to

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Matching Placebo to Ertugliflozin 5 mg
  • +8 more
  • (no location specified)
Aug 14, 2018

Covid19 Trial in Worldwide (theraputic heparin, prophylactic heparin, P2Y12)

Recruiting
  • Covid19
  • theraputic heparin
  • +4 more
  • Birmingham, Alabama
  • +101 more
Jun 28, 2022

Type 2 Diabetes Trial (drug, other, biological)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Ertugliflozin 5 mg
  • +6 more
  • (no location specified)
Aug 9, 2018